Tarsus Pharmaceuticals’ Xdemvy approved by FDA for treatment of Demodex blepharitis
Betsy Goodfellow | August 25, 2023 | News story | Medical Communications |Â Â Demodex blepharitis, FDA, Opthalmology, Tarsus Pharmaceuticals, eyedropsÂ
Tarsus Pharmaceuticals has announced that the US Food and Drug Administration (FDA) approved its drug Xdemvy (lotillaner ophthalmic solution) 0.25% for the treatment of Demodex blepharitis on 24 July 2023. The company has announced that the drug is now available throughout the US for prescription.
Xdemvy is the only treatment approved by the FDA that directly targets Demodex mites, which are the cause of Demodex blepharitis. Symptoms of the disease include redness, inflammation, missing or misdirected eyelashes, itching along the eyelid base and the presence of collarettes.
Xdemvy is a prescription eyedrop, intended to be administered twice daily, around 12 hours apart, with one drop in each eye, for up to six weeks.
Bobak Azamian, MD PhD, chief executive officer and chairman of Tarsus, commented: “We are delighted that within weeks of FDA approval, Xdemvy is now available to millions of patients with Demodex blepharitis. The efforts of our team have created incredible interest in Xdemvy, the first and only approved solution for this highly prevalent disease. I’m so appreciative of our team and our partners who’ve worked diligently to bring this product to eye care providers and patients quickly and seamlessly following regulatory approval. We are proud to introduce Xdemvy to the eye care community and look forward to its potential to significantly change the way this disease is treated.”
Betsy Goodfellow
Related Content
Alto Neuroscience’s schizophrenia treatment granted FDA Fast Track designation
Alto Neuroscience has announced that its investigational treatment for cognitive impairment associated with schizophrenia (CIAS) …
FDA approves Moderna’s updated COVID-19 vaccines targeting new variant
The US Food and Drug Administration (FDA) has approved Moderna’s updated COVID-19 vaccines, Spikevax and …
FDA approves Gamifant for macrophage activation syndrome in Still’s disease
The US Food and Drug Administration (FDA) has approved Gamifant (emapalumab-lzsg) for the treatment of …
